These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33371456)

  • 1. Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment.
    Navin I; Lam MT; Parihar R
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.
    Marofi F; Al-Awad AS; Sulaiman Rahman H; Markov A; Abdelbasset WK; Ivanovna Enina Y; Mahmoodi M; Hassanzadeh A; Yazdanifar M; Stanley Chartrand M; Jarahian M
    Front Oncol; 2021; 11():673276. PubMed ID: 34178661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors.
    Nayyar G; Chu Y; Cairo MS
    Front Oncol; 2019; 9():51. PubMed ID: 30805309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of natural killer immunotherapy in blood cancers and solid tumors.
    Sayegh M; Ma S; Yu J
    Curr Opin Oncol; 2023 Sep; 35(5):446-452. PubMed ID: 37551952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target tumor microenvironment by innate T cells.
    Li YR; Wilson M; Yang L
    Front Immunol; 2022; 13():999549. PubMed ID: 36275727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
    Matosevic S
    J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
    Ghaedrahmati F; Esmaeil N; Abbaspour M
    Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mno
    Duan J; Zhao S; Duan Y; Sun D; Zhang G; Yu D; Lou Y; Liu H; Yang S; Liang X; Ma C; Liu H; Qiu J; Gao L; Sang Y
    Adv Healthc Mater; 2024 Apr; 13(11):e2303963. PubMed ID: 38296248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.
    Douka S; Papamoschou V; Raimo M; Mastrobattista E; Caiazzo M
    Pharmaceutics; 2024 Aug; 16(9):. PubMed ID: 39339180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.
    Giuliani M; Poggi A
    Cells; 2020 Jun; 9(7):. PubMed ID: 32610578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
    Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
    Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
    Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
    BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for NK Cell Therapy of Sarcoma.
    Lachota M; Vincenti M; Winiarska M; Boye K; Zagożdżon R; Malmberg KJ
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
    Gras Navarro A; Björklund AT; Chekenya M
    Front Immunol; 2015; 6():202. PubMed ID: 25972872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies.
    Krug A; Martinez-Turtos A; Verhoeyen E
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.
    Murray S; Lundqvist A
    Hum Vaccin Immunother; 2016 Mar; 12(3):607-11. PubMed ID: 26402368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.